MedPharm Receives Investment from Ampersand Capital Partners

MedPharm, a Guilford, UK-based developer of topical and transdermal products for drug developers, received an investment from Ampersand Capital Partners.

The amount of the deal was not disclosed.

The company will use the funds to expand its service offering in topical and transdermal pharmaceutical development and manufacturing, as well as increase international CDMO market coverage.

Founded almost 20 years ago by Dr. Andrew Muddle (CEO) and Prof. Marc Brown (CSO), who will remain with the company following this deal, MedPharm develops topical and transdermal products for the pharmaceutical drug development communities worldwide. The company’s services currently encompass formulation development, performance testing and clinical trials manufacturing at its facilities in Guildford, UK and Durham, NC, US.



Join the discussion